Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,230 recruiting studies in this area right now.
By phase
- Not applicable3,147
- Phase 21,063
- Phase 1819
- Phase 1/Phase 2442
- Phase 3425
- Phase 4238
- Phase 2/Phase 396
Top conditions
- Multiple Sclerosis343
- Multiple Myeloma332
- Asthma194
- Lymphoma182
- Rheumatoid Arthritis140
- Type 1 Diabetes133
- Atopic Dermatitis129
- Systemic Lupus Erythematosus125
- Acute Lymphoblastic Leukemia122
- HIV Infections116
- Chronic Lymphocytic Leukemia100
- Autoimmune Diseases81
- Follicular Lymphoma74
- Diabetes Mellitus, Type 169
- Hodgkin Lymphoma67
- Rheumatoid Arthritis (RA)66
- Leukemia64
- Type 1 Diabetes Mellitus63
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China91
- National Institute of Allergy and Infectious Diseases (NIAID)90
- National Cancer Institute (NCI)73
- Assistance Publique - Hôpitaux de Paris70
- M.D. Anderson Cancer Center63
- Novartis Pharmaceuticals60
- AstraZeneca57
- City of Hope Medical Center47
- Mayo Clinic46
- Memorial Sloan Kettering Cancer Center44
Where studies are running
- California491
- Maryland195
- Alabama175
- Florida144
- Arizona142
- New York123
- Massachusetts119
- Texas118
- Illinois81
- Colorado77
Recruiting studies6,230 total
- NCT07128641RecruitingPhase 2
Odronextamab for early follicular lymphoma without prior treatment
This trial tests a new immunotherapy drug, odronextamab, for people with slow-growing follicular lymphoma that hasn't been treated yet and isn't causing big problems. It aims to see if the drug can control the cancer with fewer side effects.
Boston, MassachusettsAges 18 years+ - NCT07128966Recruiting
Collect biospecimens and health data for research
This study collects blood, saliva, or other biospecimens and health information from people with certain medical conditions. Your samples and data will help researchers better understand diseases and develop new treatments.
Lexington, MassachusettsAges 18–90 - NCT07129642RecruitingEarly Phase 1
Donor CAR-T cells for hard-to-treat Graves' disease
This trial tests a new type of cell therapy called CAR-T cells made from a donor. The cells target B cells that may drive Graves' disease. It's for people whose Graves' disease has not gotten better with usual treatments.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT07132567Recruiting
Studying safety and effectiveness of Poteligeo for certain skin lymphomas
This study is tracking the safety and effectiveness of a drug called Poteligeo (mogamulizumab) for adults with mycosis fungoides or Sézary syndrome who have already tried at least one body-wide treatment. It is a post-market surveillance study, meaning the drug is already approved, and doctors are gathering real-world information about how well it works and any side effects.
Busan, Busan Metropolitan CityAges 19 years+ - NCT07133113Recruiting
Effects of treatments in autoimmune encephalitis
This study follows patients with autoimmune encephalitis (brain inflammation caused by the immune system) to see how treatments affect them in the medium term. It may help doctors learn which treatments work best for people with this condition.
BronAges Any age - NCT07133659RecruitingPhase 4
New starting dose of avatrombopag for immune thrombocytopenia
This study tests a modified starting dose of avatrombopag, a medication that helps raise platelet counts, in adults with immune thrombocytopenia (ITP) who have not responded well to first-line steroid treatments. The goal is to see if this new dosing is effective and safe.
BaghdadAges 18 years+ - NCT07135466RecruitingPhase 1/Phase 2
Anti-CD22 CAR T-cell therapy for B-cell blood cancers
This trial tests a new treatment using your own immune cells (T-cells) that are modified to find and attack cancer cells with a marker called CD22. It is for people with B-cell blood cancers that have come back or not responded to at least two prior treatments, including a type of immunotherapy called CAR T-cell therapy.
Ramat Gan, GAges 1–80 - NCT07135583Recruiting
Breathing recovery after spinal cord injury
This study tests non-invasive treatments to help people with chronic spinal cord injury improve their breathing. It may be a good fit if you have had a spinal cord injury for at least a year and have weak breathing muscles.
Philadelphia, PennsylvaniaAges 18–70 - NCT07135752Recruiting
Comparing digital tests in people with early MS or MRI signs
This trial studies whether digital tests can detect early changes in people with radiologically isolated syndrome (RIS) or multiple sclerosis (MS) who have normal neurological exams. It may help identify subtle symptoms earlier.
NiceAges 18–60 - NCT07136025Recruiting
Finding treatable traits in severe asthma for personalized care
This study aims to identify specific treatable traits in people with severe asthma and build a personalized treatment plan. It will help doctors understand which treatments might work best for you based on a detailed evaluation.
Beijing, Beijing MunicipalityAges 18–80 - NCT07136844Recruiting
Walking and arm movement study for nerve and muscle conditions
This study uses motion analysis to understand walking and arm function in adults with certain neurological or metabolic diseases. The goal is to find patterns that help doctors better manage these conditions.
LiègeAges 18 years+ - NCT07137494RecruitingPhase 1
CAR T-cell therapy for CNS lymphoma
This trial tests a new type of CAR T-cell therapy (MB-CART19.1) for people with central nervous system lymphoma (CNSL) that has come back or not responded to treatment. It aims to see if this therapy can help treat the lymphoma in the brain or spinal fluid.
Basking Ridge, New JerseyAges 18 years+ - NCT07138144RecruitingPhase 4
Switching to a two-drug HIV pill vs. staying on three drugs
This study tests whether switching to a simpler, two-drug HIV pill (dolutegravir/lamivudine) is as safe and effective as staying on a three-drug regimen. It is for people whose HIV is already well-controlled and who are currently taking Biktarvy or Triumeq.
Mexico City, Mexico CityAges 18–70 - NCT07138196RecruitingPhase 1
Adrixetinib for hard-to-treat chronic GvHD
This trial tests an experimental drug called adrixetinib (Q702) for people with active chronic graft-versus-host disease that has not responded well to standard treatments. It aims to see if the drug can help control your symptoms when other options have stopped working.
BarcelonaAges 18 years+ - NCT07138209RecruitingPhase 3
Comparing QLS32015 to standard treatments for multiple myeloma
This trial tests a new drug, QLS32015, against two common treatments for multiple myeloma that has come back or not responded to therapy. It may be an option for people who have already tried several treatments.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07138547RecruitingPhase 1/Phase 2
Eliglustat plus CD30 immunotherapy for CD30+ lymphoma
This trial tests a combination of two medicines (eliglustat and a CD30-targeted immunotherapy) for people with a type of lymphoma that has a specific marker called CD30. It aims to see if this combination can help when standard treatments have already been used.
Beijing, Beijing MunicipalityAges 18–75 - NCT07138729Recruiting
Imaging test for rheumatoid arthritis inflammation
This trial tests a new imaging scan (SPECT) that uses a special tracer (99mTc-TCR-FAPI) to see inflammation in the joints of people with rheumatoid arthritis. It aims to help doctors better understand and track disease activity.
Beijing, Beijing MunicipalityAges 18–75 - NCT07139509RecruitingPhase 1
Dual-targeting CAR-T cell therapy for relapsed multiple myeloma
This trial tests a new type of immune cell therapy using donated umbilical cord blood cells that are modified to target two proteins (BCMA and CD19) on myeloma cells. It is for people whose multiple myeloma has come back or is not responding to at least three prior treatments, including a proteasome inhibitor, an immunomodulatory drug, or an anti-CD38 antibody.
Xi’an, ShanxiAges 18–75 - NCT07139743RecruitingPhase 1
Obe-cel for progressive multiple sclerosis that is getting worse
This study tests a new treatment called obe-cel, a type of CAR T-cell therapy, for people with progressive multiple sclerosis that hasn't responded to other treatments. It aims to see if this therapy can slow or stop the disease from getting worse.
Redwood City, CaliforniaAges 18–60 - NCT07139873RecruitingPhase 3
Study of DZD8586 vs. standard care for relapsed CLL or SLL
This trial tests a new drug, DZD8586, against other standard treatments for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or stopped responding to prior therapy. The goal is to see if DZD8586 works better or has fewer side effects.
Nanjing, JiangsuAges 18 years+ - NCT07139899Recruiting
Mucus Plugs and Lung MRI in Severe Asthma
This study is looking at how mucus plugs in the airways affect lung function in people with severe asthma. If you are about to start a new injectable asthma treatment (dupilumab, tezepelumab, or benralizumab), you may be able to join and get a special type of lung MRI to see how your lungs are doing.
Durham, North CarolinaAges 18–65 - NCT07142252RecruitingPhase 2
New drug for recently diagnosed type 1 diabetes
This trial tests a new medicine (rezpegaldesleukin) to see if it can help preserve the body's ability to make some insulin in people recently diagnosed with type 1 diabetes. It's for children and adults diagnosed within the past 100 days.
Aurora, ColoradoAges 8–45 - NCT07142473Recruiting
Mastocytosis Registry from Childhood to Adulthood
This registry collects information from people with mastocytosis (a condition where too many mast cells build up in the skin or organs) who are treated at a specific clinic in Italy. The goal is to better understand how the disease changes over time from childhood to adulthood.
Pavia, PaviaAges 6 years+ - NCT07142681Recruiting
How adults' diets change when caring for a child with new type 1 diabetes
This study looks at how the eating habits of adults change when they care for a child newly diagnosed with type 1 diabetes. The goal is to understand what you go through and find better ways to support families.
BarcelonaAges 18 years+
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,230 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,763 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.